Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IV Study of Respiratory Syncytial Virus Monoclonal Antibody Therapy in High-risk Infants and Toddlers

Trial Profile

Phase IV Study of Respiratory Syncytial Virus Monoclonal Antibody Therapy in High-risk Infants and Toddlers

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Apr 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palivizumab (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CARESS
  • Most Recent Events

    • 30 Mar 2020 Results of subgroup analysis of three subgroups: immunocompromised group: n=214, complex medical disorders group: n=4283 and standard indications group: n=20506, assessing respiratory illness hospitalization and RSV-related hospitalization hazard ratios were published in the Pediatric Infectious Disease Journal
    • 30 Nov 2018 Results (n=21,107) assessing risk of respiratory illness- and RSV-related hospitalizations (RIH and RSVH, respectively) among infants prophylaxed for CDH, standard indications (SI), and those without increased risk (NR), published in the Clinical Infectious Diseases.
    • 04 May 2018 Results (n=23,228) published in the European Journal of Clinical Microbiology and Infectious Diseases.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top